A U.S. patient diagnosed with advanced non-small cell lung cancer received treatment with Ivonescimab at the Jiahui International Cancer Center in Shanghai after exhausting standard therapies in the United States. The 70-year-old patient, who also has Parkinson’s disease, previously underwent treatment at MD Anderson Cancer Center. Following a remote consultation, the patient’s family decided to pursue treatment in China, where Ivonescimab is approved for use against solid tumors.
During the course of treatment, the patient experienced immune-related complications that required intensive care support. The hospital coordinated a multidisciplinary medical response involving oncology, neurology, and intensive care specialists, along with consultation from a clinical investigator involved in Ivonescimab research. After stabilization, treatment continued with the goal of managing disease progression. Ivonescimab is a bispecific antibody designed to target both PD-1 and VEGF-A pathways, a mechanism intended to enhance immune response while affecting tumor blood vessel growth.
The case highlights growing international interest in oncology therapies developed and approved within China.
Why it matters
Cross-border access to emerging oncology therapies highlights the global impact of novel immunotherapy treatments and evolving international pathways for advanced cancer care.
Source Attribution
Source: Jiahui International Cancer Center
